临床肝胆病杂志2024，Vol.40Issue(5)：1032-1038,7.DOI:10.12449/JCH240526
原发性硬化性胆管炎药物治疗进展
Advances in drug therapy for primary sclerosing cholangitis
摘要
Abstract
Primary sclerosing cholangitis(PSC)is a cholestatic disease characterized by chronic progressive bile duct inflammation and has a low incidence rate and poor prognosis in China.There is still no drug therapy that can change the course of PSC,and liver transplantation is the only effective treatment for PSC,with a 5-year survival rate of 85%after transplantation.Drug therapy for PSC is facing great challenges based on the current status of PSC.At present,drugs for the treatment of PSC are in the stage of clinical trials and have shown certain application prospect,among which ursodeoxycholic acid is the most widely studied and commonly used drug.In addition,there are many emerging drugs in the pipeline.This article summarizes the latest advances in drug therapy for PSC.关键词
胆管炎,硬化性/熊去氧胆酸/奥贝胆酸/药物疗法Key words
Cholangitis,Sclerosing/Ursodeoxycholic Acid/Obecholic Acid/Drug Therapy引用本文复制引用
盛夏,纪庆明,李昕宇,王丽宏,牛俊奇..原发性硬化性胆管炎药物治疗进展[J].临床肝胆病杂志,2024,40(5):1032-1038,7.基金项目
国家自然科学基金(82200666) National Natural Science Foundation of China(82200666) （82200666）
